Cytomegalovirus Infection Clinical Trial
Official title:
Phase II, Multicentric, Prospective and Opened Clinical Trial of Advance Valganciclovir Treatment of CMV in Allogenic Hematopoietic Progenitors Transplant
Verified date | September 2009 |
Source | PETHEMA Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | Spain: Ministry of Health |
Study type | Interventional |
PRINCIPAL ENDPOINT To value valganciclovir efficacy in advance treatment of CMV in patients
received allogenic transplant with a uniform treatment.
SECONDARY ENDPOINT To value valganciclovir security in advance treatment of CMV in in
patients received allogenic transplant with a uniform treatment.
The security will be valued by the % of patients that:
Will have negative CMV Neutropenia <1000 neutrophils/mm3 or <500 neutrophils/mm3 in the
first 35 days of treatment - follow-up Renal toxicity in the first 35 days of treatment -
follow-up (defined by elevated creatinine >1mg/dL or twice the basal value) CMV illness
during the treatment or in the next 2 months Blood Antigenemia / PCR positive in the next
2months of treatment
This dates Hill be compared with a patients control group treated with intravenous
valganciclovir
Status | Completed |
Enrollment | 132 |
Est. completion date | September 2009 |
Est. primary completion date | September 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 2 Years and older |
Eligibility |
Inclusion Criteria: - Patients > 18 years old - Any patients with allogenic TPH - Following in post-TPH with antigenemia or PCR-CMV - CMV in blood test detected by antigenemia or PCR before the day 180 post-TPH - The beginning of treatment must be Duch early as possible. Maximum in the 72 hours from the antigenemia or PCR-CMV detection - Be the first or second time of a CMV infection - Sign the informed consent - Pregnancy negative test in fertile age patients Exclusion Criteria: - Patients received auto or syngenic TPH - Patients <50 kg weight - Known allergy or hypersensibility patients to valganciclovir, ganciclovir or aciclovir - Digestive intolerant: nauseous, vomit and or diarrhea that could difficult oral administration of valganciclovir - Patients that presents CMV infection or that is being evaluated for suspected CMV - Patients that have presented >2 CMV infection episode, before the current one - Severe liver disease defined by bilirubin = 10mg/dL - Treated with: foscarnet, ganciclovir, cidofovir or another antiviral drug active to CMV, in the previous 30 days at the current episode - Neutrophils < 500 /µL at the beginning of valganciclovir treatment. Patients with >500 PMN/µL and < 1000/µL must start a G-CSF treatment to get neutrophils value > 1000/µL - Platelets < 25/mm3 even receiving transfusion - Clearance Creatinine < 10mL/min or dialysed patients - Pregnancy or lactant women - Other contraindication detailed in the "filling card" - Previous inclusión in this study at the treated group. Is allowed that a patient participate as a control case and after that receive valganciclovir treatment in after CMV episode |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Clínico y Provincial de Barcelona | Barcelona | |
Spain | Hospital Universitario "Germans Trias i Pujol" | Barcelona | |
Spain | Hospital general de Jerez de la Frontera | Jerez de la Frontera | |
Spain | Hospital Universitario de la Princesa | Madrid | |
Spain | Hospital Universitario La Paz | Madrid | |
Spain | Hospital Universitario Ramón y Cajal, Madrid | Madrid | |
Spain | Hospital Universitario Morales Meseguer, Murcia | Murcia | |
Spain | Hospital Clínico Universitario de Salamanca | Salamanca |
Lead Sponsor | Collaborator |
---|---|
PETHEMA Foundation |
Spain,
Burri M, Wiltshire H, Kahlert C, Wouters G, Rudin C. Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl. Pediatr Infect Dis J. 2004 Mar;23(3):263-6. — View Citation
Ciancio G, Burke GW, Mattiazzi A, Leibovici Z, Dowdy L, Roth D, Kupin W, Rosen A, Jorge D, Cirocco RE, Miller J. Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation. Clin Transplant. 2004 Aug;18(4):402-6. — View Citation
Clark BS, Chang IF, Karpen SJ, Herrera L, Scott JD, Bristow LJ, Quirós-Tejeira RE, Goss JA. Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients. Transplantation. 2004 May 15;77(9):1480. — View Citation
Cvetkovic RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs. 2005;65(6):859-78. Review. — View Citation
Einsele H, Reusser P, Hertenstein B, Bornhäuser M, Kröger N, Kahls P, et al. Pharmakokinetics of Valganciclovir after AlloSCT: A Fixed Oral Dose Can Be Used for Preemptive Therapy in Patients with Normal Body Weight - Even with Intestinal GVHD. Blood 2004;104(11):abstract 2239.
Ljungman P, de La Camara R, Milpied N, Volin L, Russell CA, Crisp A, Webster A; Valacyclovir International Bone Marrow Transplant Study Group. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood. 2002 Apr 15;99(8):3050-6. — View Citation
Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002 Apr 15;34(8):1094-7. Epub 2002 Mar 11. Review. — View Citation
Ljungman P, Reusser P, de la Camara R, Einsele H, Engelhard D, Ribaud P, Ward K; European Group for Blood and Marrow Transplantation. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant. 2004 Jun;33(11):1075-81. — View Citation
Nichols WG, Corey L, Gooley T, Drew WL, Miner R, Huang M, Davis C, Boeckh M. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood. 2001 Feb 15;97(4):867-74. — View Citation
Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD; Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004 Apr;4(4):611-20. — View Citation
Razonable RR, Paya CV. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert Rev Anti Infect Ther. 2004 Feb;2(1):27-41. Review. — View Citation
Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, Finke J, Cordonnier C, Link H, Ljungman P; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002 Feb 15;99(4):1159-64. — View Citation
* Note: There are 12 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To value valganciclovir efficacy in advance treatment of CMV in patients received allogenic transplant with a uniform treatment. | 1 year | No | |
Secondary | To value valganciclovir security in advance treatment of CMV in in patients received allogenic transplant with a uniform treatment. | 1 year | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00023036 -
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
|
||
Terminated |
NCT01037712 -
In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir
|
Phase 4 | |
Completed |
NCT00370006 -
Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM
|
Phase 1 | |
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT01552369 -
CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")
|
Phase 4 | |
Completed |
NCT00223925 -
Maribavir for Prevention of CMV After Stem Cell Transplants
|
Phase 2 | |
Active, not recruiting |
NCT05085366 -
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
|
Phase 3 | |
Completed |
NCT01220895 -
Alternate Donor Study of Pre-Emptive Cellular Therapy
|
Phase 2 | |
Completed |
NCT00942305 -
Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
|
Phase 2 | |
Completed |
NCT00373412 -
Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge
|
Phase 1 | |
Completed |
NCT05105048 -
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647
|
Phase 1 | |
Completed |
NCT03382405 -
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
|
Phase 1 | |
Completed |
NCT02454699 -
Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03910478 -
Dried Blood Spot Testing of CMV Detection in HCT Recipients
|
N/A | |
Completed |
NCT01354301 -
Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate
|
Phase 4 | |
Active, not recruiting |
NCT01473849 -
Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients
|
N/A | |
Completed |
NCT00880789 -
Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus
|
Phase 1 | |
Completed |
NCT00817908 -
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
|
N/A | |
Completed |
NCT00273143 -
A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients.
|
Phase 1 | |
Completed |
NCT00194155 -
Cytomegalovirus (CMV) Infection in Pregnancy
|
N/A |